BSD launches rectal cancer treatment study | MassDevice

December 20, 2012 by MassDevice staff

BSD Medical initiates a Phase I/II clinical study of its hyperthermia system for the treatment of patients with recurrent rectal cancer.

BSD Medical Corp.?(NSDQ:BSDM) initiated its Phase I/II HyRec-Trial, evaluating its BSD-2000 Hyperthermia System to treat patients with locally recurrent rectal cancer.

The clinical trial, which has been approved by the German Cancer Society, will enroll 59 patients to evaluate the feasibility and the efficacy of adding hyperthermia to a multimodal treatment regimen, the company said.

Sign up to get our free newsletters delivered right to your inbox.

Colorectal cancer is the 2nd leading cause of death in the U.S. and the 4th most common form of cancer worldwide, according to the press release.

The BSD-2000 Hyperthermia System delivers localized therapeutic heating in combination with chemotherapy and radiofrequency energy, BSD said.

Researchers said radiotherapy combined with chemotherapy and deep hyperthermia can improve response, local control and survival rates in certain patients with rectal cancer, 2 studies showed.

The multicenter study will be sponsored by the University of Erlangen Medical School and led by Dr. Oliver Ott, associate professor of the department of radiation oncology at Erlangen.

Permalink

Source: http://www.massdevice.com/news/bsd-launches-rectal-cancer-treatment-study

mike brown bcs rankings jay cutler applebees jeff gordon veterans day world war z